Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
暂无分享,去创建一个
Linda Mol | Miriam Koopman | O. Dalesio | D. Richel | C. Punt | E. Voest | M. Koopman | F. Erdkamp | J. Tol | J. V. van Krieken | G. Creemers | A. Cats | J. Dijkstra | Emile E Voest | Cornelis J A Punt | Annemieke Cats | N. Antonini | Otilia Dalesio | Johan H J M van Krieken | Jolien Tol | Cees J Rodenburg | Geert J M Creemers | Jolanda G Schrama | Frans L G Erdkamp | Allert H Vos | Cees J van Groeningen | Harm A M Sinnige | Dirk J Richel | Jeroen R Dijkstra | Marianne E Vink-Börger | Ninja F Antonini | C. Rodenburg | J. Schrama | C. V. van Groeningen | M. E. Vink-Börger | H. Sinnige | J. van Krieken | L. Mol | A. Vos | C. V. Groeningen | Johan H. J. M. van Krieken | Miriam Koopman | Cees J van Groeningen | Jeroen R. Dijkstra | Johan H J M van Krieken | Otilia Dalesio | J. H. V. van Krieken | Harm A. M. Sinnige | J. K. Tol | A. R. M. Cats | G. J. M. S. C. J. Creemers | J. G. Erdkamp | van Groeningen | Dijkstra | Vink-Börger | van Krieken | C.J.A. Punt | Cees J Rodenburg | Frans L G Erdkamp | Cees J van Groeningen | Dirk J Richel | Emile E. Voest | Otilia Dalesio | D. Richel | Frans Erdkamp | O. Dalesio | C. Punt | J. V. van Krieken
[1] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[2] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[3] C. Bokemeyer,et al. 3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): a large-scale phase II study, OPUS , 2007 .
[4] C. Bokemeyer,et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience , 2008 .
[5] M. Koopman,et al. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] L. Ellis,et al. Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. , 2002, European journal of cancer.
[7] A. Lièvre,et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[10] R. Berardi,et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] L. Ellis,et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors , 2001, British Journal of Cancer.
[12] M. Gonen,et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Richard J Stephens,et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial , 2007, The Lancet.
[14] D. Hicklin,et al. Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted Therapy , 2006, Clinical Cancer Research.
[15] M. Christian,et al. [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.
[16] Richard L Schilsky,et al. Cetuximab in the treatment of colorectal cancer. , 2004, Clinical advances in hematology & oncology : H&O.
[17] F. Kabbinavar,et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] E. Van Cutsem,et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] Sabine Tejpar,et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience , 2008 .
[20] G. Fontanini,et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] T. Shanafelt,et al. Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. Köhne,et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial , 2007 .
[23] R. Greil,et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Carrato,et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] C. Bokemeyer. Bleomycin in testicular cancer: will pharmacogenomics improve treatment regimens? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Linda Mol,et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial , 2007, The Lancet.